The use of genetic markers to determine risk for prostate cancer at prostate biopsy

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8391-8397

  Nam, Robert K ^a,d   Zhang, William W ^a   Jewett, Michael A S ^b   Trachtenberg, John ^b   Klotz, Laurence H ^a   Emami, Marjan ^a   Sugar, Linda ^a   Sweet, Joan ^b   Toi, Ants ^b   Narod, Steven A ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; MONOPHENOL MONOOXYGENASE; PANCREATIC RIBONUCLEASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CHK2 GENE; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; ENDOSTATIN GENE; FAMILY HISTORY; GENE DELETION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; GSTT1 GENE; HOGG1 11657 GENE; HOGG1 326 GENE; HOMOZYGOSITY; HRAS1 GENE; HUMAN; HUMAN TISSUE; KLK2 GENE; MAJOR CLINICAL STUDY; MALE; MCRA GENE; MCRV GENE; MSR1 GENE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE; RNASEI GENE; SYMPTOMATOLOGY; TNF308 GENE; TYROSINASE GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 28544452991     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1226     Document Type: Article

References (41)

1. von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guidelines for the early detection of prostate cancer. Cancer 1997; 80:1805-7.
2. Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787-91.
3. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171: 2239-44.
4. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-3.
5. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
6. Correa-Cerro L, Berthon P, Haussler J, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999;105:281-7.
7. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 1997;57: 1020-2.
8. Nam RK, Toi A, Vesprini D, et al. The V89L polymorphism of the SRD5A2 gene predicts prostate cancer presence and progression. Urology 2000; 57:199-204.
9. Lewis DFV, Lee-Robichaud P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J Steroid Biochem Mol Biol 1998;66: 217-33.
10. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-9.
11. Gsur A, Bernhofer G, Hinteregger S, et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87:434-7.
12. Halman CA, Stampfer MJ, Giovannucci E, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001;10:743-8.
13. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-5.
14. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Cancer 1992;70: 2861-9.
15. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000; 60:839-41.
16. Xu J, Meyers DA, Sterling DA, et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 2002;11:664-9.
17. Medeiros R, Morais A, Vasconcelos A, et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 2002;53:88-94.
18. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
19. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-4.
20. Rebbeck TR, Walker AH, Jaffe JM, White DI, Wein AJ, Malkowicz SB. Glutathione S-transferase-μ (GSTM1) and θ (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8: 283-7.
21. Oh BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at - 308, and 488 regions of the tumor necrosis factor-α (TNF-α) gene in patients with prostate cancer. J Urol 2000;163:1584-7.
22. Nam RK, Zhang W, Jewett MAS, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1429-37.
23. Nam RK, Zhang WW, Trachtenberg J, et al. A Single nucleotide polymorphism of the human kallikrein-2 gene (KLK2) highly correlates with serum HK2 levels and their combination significantly enhances prostate cancer detection. J Clin Oncol 2003;21: 2312-9.
24. Iughetti P, Suzuki O, Godoi PH, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001;61:7375-8.
25. Luscombe CJ, French ME, Liu S, et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001;85:1504-9.
26. Luscombe CJ, French ME, Liu S, et al. Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001;22:1343-7.
27. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003;72:270-80.
28. Xu J, Zheng SL, Turner A, et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 2002;62:2253-7.
29. Bonafe M, Barbi C, Olivieri F, et al. Anallele of HRAS1 3′ variable number of tandem repeats is a frailty allele: implication for an evolutionarily-conserved pathway involved in longevity. Gene 2002;286:121-6.
30. Barry MJ, Fowler FJJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148: 1549-57.
31. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
32. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
33. 462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32:581-3.
34. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993;329:517-23.
35. Nam RK, Toi A, Trachtenberg J, et al. Variation in patterns of practice in diagnosing screen-detected prostate cancer. BJU Int 2004;94:1239-44.
36. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151:1571-4.
37. Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schroder FH. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 1998;160:2121-5.
38. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1,2,3 and 4: when should we stop? J Urol 2001;166:1679-83.
39. Durkan GC, Greene DR. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int 1999;83:424-8.
40. Hayek OR, Noble CB, de la Taille A, Bagiella E, Benson MC. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free: total ratio) in men with prior negative prostatic biopsies. Curr Opin Urol 1999;9:371-5.
41. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9.